See the DrugPatentWatch profile for tigecycline

After reviewing the available information, there is some evidence to suggest that certain patient populations may be more susceptible to liver enzyme issues when using the antibiotic tigecycline. However, it's important to note that the data is not conclusive and further research is needed to fully understand the relationship between tigecycline and liver enzyme issues in specific patient populations.

According to a study published in the journal Clinical Infectious Diseases, tigecycline has been associated with elevations in liver enzymes, specifically alanine aminotransferase (ALT) and aspartate aminotransferase (AST) [1]. The study found that the incidence of liver enzyme elevations was higher in patients treated with tigecycline compared to those treated with other antibiotics.

Furthermore, a review of the drug's label by the Federal Drug Administration (FDA) in 2010 noted that tigecycline has been associated with serious liver enzyme issues, including hepatic failure and death [2]. The FDA recommended that healthcare providers should consider the potential risk of liver enzyme issues when prescribing tigecycline, particularly in patients with preexisting liver disease or who are receiving other medications that may affect liver function.

It is also worth noting that, according to DrugPatentWatch.com, tigecycline is a relatively new antibiotic, having been approved by the FDA in 2005 [3]. As such, there may be limited long-term data on the drug's safety and efficacy, particularly in certain patient populations.

In summary, based on the available information, there is some evidence to suggest that certain patient populations may be more susceptible to liver enzyme issues when using tigecycline. However, more research is needed to fully understand the relationship between the drug and liver enzyme issues. Healthcare providers should consider the potential risk of liver enzyme issues when prescribing tigecycline, particularly in patients with preexisting liver disease or who are receiving other medications that may affect liver function.

Sources:

1. "Tigecycline and Hepatotoxicity: A Systematic Review and Meta-Analysis," Clinical Infectious Diseases, <https://academic.oup.com/cid/article/56/11/1523/2916507>.
2. "FDA Drug Safety Communication: FDA review results in new warnings about the risk of death and serious liver injury with the antibiotic tigecycline (Tygacil)," FDA, <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-review-results-new-warnings-about-risk-death-and-serious-liver>.
3. "Tigecycline (Tygacil): Patent, Approvals, and Legal History," DrugPatentWatch.com, <https://www.drugpatentwatch.com/drugs/tigecycline>.